Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen and Nagendra Sastry Yarla Pages 156 - 163 ( 8 )
Background: Cancer is a series of different disease (>200 different sub-types) with an identical feature of unlimited growth, invasive and multi-step/multi-level metastasis processes.
Objective: Individualized cancer therapies/personalized cancer therapies will undergo a dramatic evolution to cope with this disease diversity and a complexity of tumor genes/biomarkers.
Methods: The next generation of personalized cancer therapy must simultaneously contain information of pharmacology (drug sensitivity or drug combination), oncology (tumor etiopathological information), computational network (predictive of cancer risks and therapeutic efficacy), toxicology (adverse side-effects and human mortality), artificial intelligence and patient’s desire (decision-aid), especially technology merge.
Results: Future multi-functional approach is inevitable. After all, multi-functional personalized cancer therapy (collective and balanced regime/paradigms) might take formation in the future.
Conclusion: A reliable, safe, effective and collective platform can be established through further scientific and technical approaches in the clinic.
Individualized cancer therapy, personalized medicine, pharmacology, neoplasm pathology, drug combinations, neoplasm metastasis, mathematics, computational network, decision aid.
Shanghai University, School of Life Sciences, Shanghai University, Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, Shanghai University, Shanghai 200444, Medical School, Shanghai Jiao-Tong University, Shanghai, Divisions of Biochemistry & Chemistry, City University of New York School of Medicine, 160 Convent Avenue, New York, NY10031